Rezaul Karim

I completed my PhD in cancer immunology at the University of Leiden (Professor Cornelis Melief) followed by a postdoctoral fellowship in cancer biology in Vienna (Professor Josef Penninger).

My industry experience began at a NASDAQ-listed biotech company, where I focused on the preclinical development of bispecific antibody-mediated cancer immunotherapies. Later, I worked at a WHO-Utrecht University Center of Excellence, contributing to CMC and non-clinical evaluations of biologics.

At Starodub, my role primarily involves CMC and non-clinical development of biologics, small chemical pharmaceuticals, advanced therapy medicinal products, cell therapies, mRNA therapeutics, vaccines, medical devices and combination products across a broad range of therapeutic areas.

In preclinical space, I bring over 20 years of experience (mostly hands-on) in research and development, acquired in both biotech settings and world-renowned academic laboratories. My expertise spans state-of-the-art in vitro, in vivo, and in situ preclinical studies.

At Starodub, I have contributed in the preparation/assessment of non-clinical development strategies and plans, designing non-clinical pharmacology, pharmacokinetics and toxicology studies, conducting due diligence and gap assessments, selecting and managing CROs, writing of non-clinical parts of regulatory documents, interactions with regulatory authorities for scientific advice, (non-)clinical development and marketing authorization. My work also includes toxicological risk assessments, as well as evaluating the biological safety and biocompatibility of medical devices and combination products.

Collaborating with the expert team at Starodub to drive drug development forward is both fulfilling and inspiring to me.